glp1 gip tirzepatide (TZP) differentially induces internalization of the and Frontiers | GLP-1/GIP dual agonist

Combination therapy should only be reviewed by a licensed provider because dosing, monitoring, and safety risks become more complex

Due to its high incidence and disability rates, DKD poses a serious threat to human health and represents a significant public health burden

- to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease

If you havent seen any improvement in your first couple of months, dont lose faith

Tesofensine May Be Better For: Patients who strongly prefer oral medication over injections Individuals whose eating patterns are driven primarily by cravings, emotional eating, or reward-seeking behavior (dopamine-mediated eating) Patients who have not responded adequately to GLP-1 medications Those who tolerate stimulant-type medications well Individuals without significant cardiovascular risk factors Semaglutide May Be Better For: Patients with type 2 diabetes or prediabetes (dual benefit of weight loss and glycemic control) Individuals with cardiovascular disease or elevated cardiovascular risk (proven cardioprotective benefit) Patients who prefer weekly dosing over daily medication Those who experience primarily volume-driven overeating rather than craving-driven eating Individuals with a history of anxiety or insomnia (since semaglutide does not have stimulant properties) Combination Therapy Some physicians prescribe tesofensine and semaglutide together, leveraging their complementary mechanisms tesofensine addressing central nervous system-mediated cravings while semaglutide handles peripheral satiety and metabolic improvements